R&D Why physiological pacing is changing the future of cardiac r... Increasingly, electrophysiologists are exploring approaches that activate the heart through its intrinsic conduction pathways.
News FDA won't approve Summit, Akeso's ivonescimab The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.